Lacuna Partners and Wuhan Asia General Hospital Establish Strategic Collaboration to Advance Medical Innovation and Technology Commercialization

On December 8, the unveiling ceremony for the “Yaxin–Legend Capital Innovative Technology Transfer Center” was held at Wuhan Yaxin General Hospital, marking the establishment of a deep strategic partnership between Legend Capital and Wuhan Yaxin General Hospital to promote the translation of innovative technologies.

Xie Zhaoji, Managing Director of Wuhan Yaxin General Hospital; Lin Yixian, Director of the Innovation Center at Yaxin Group; Ye Hong, Managing Director of Wuhan Asia Heart Hospital; Wang Jianfei, Managing Director at Legend Capital; Qi Fei, Director at Legend Capital; medical experts from Yaxin Hospital; and representatives from more than ten healthcare companies invested by Legend Capital attended the unveiling ceremony.

From left to right: Xie Zhaoji, Managing Director of Wuhan Yaxin General Hospital; Ye Hong, Managing Director of Wuhan Asia Heart Hospital; Lin Yixian, Director of the Innovation Center at Yaxin Group; and Wang Jianfei, Managing Director of Legend Capital.

Group Photo of Attendees

Both parties will leverage the “Yaxin–Legend Capital Innovative Medical Technology Translation Center” as a foundation to conduct regular industry exchange activities, such as salons on medical translation themes, roadshows for innovative projects in the cardiovascular field, and the annual conference of the Innovative Medical Application Translation Center.

Partner enterprises of the “Yaxin–Legend Capital Medical Innovation Technology Transfer Center” can fully leverage the resources of Yaxin Hospital Group and its affiliated hospitals to serve as clinical trial or application sites for their new products or technologies. They will receive comprehensive support from physicians throughout the clinical trial process, including expert consultations, technical guidance, and clinical skills training. Additionally, they will benefit from professional advice and guidance from Legend Capital in areas such as corporate development, equity financing, and mergers and acquisitions, and may also secure investment from Legend Capital and its associated investment partners.

Address by Xie Zhaoji, Managing Director of Wuhan Yaxin General Hospital

Xie Zhaoji, Managing Director of Wuhan Yaxin General Hospital, stated that private hospitals face daily survival pressures due to financial constraints, whereas medical research and innovation require long-term resource investment. Therefore, the collaboration between Yaxin and Legend Capital is of significant importance. By integrating resources from healthcare, research, enterprise, and capital sectors to establish industrial linkages, this partnership will effectively promote clinical exchange and cooperation, and facilitate the translation and implementation of innovative medical research achievements.

Remarks by Wang Jianfei, Managing Director of Legend Capital

Wang Jianfei, Managing Director at Legend Capital, stated that innovation will be the driving force behind the development of private hospitals in China over the next decade. Legend Capital is honored to have established a deep strategic partnership with Yaxin Hospital. After a year of extensive exploration and repeated discussions, both parties successfully launched the Innovation Translation Center. It is hoped that the center will make significant contributions to the translation of scientific and technological achievements in the fields of healthcare and pharmaceuticals.

“At 20, Yaxin and at 19, Legend Capital are like two vibrant young entities poised to generate even greater synergy in their future collaboration.” Wang Jianfei expressed strong confidence in the prospective partnership between the two parties.

Lin Yixian, Director of the Innovation Center at Yaxin Group, Shares Insights on “Development Trends in Cardiovascular Technology”

Following the unveiling ceremony, experts and industry leaders from the medical and corporate sectors engaged in rich and insightful exchanges on development trends, cutting-edge technologies, and clinical practices in the cardiovascular field.

Lin Yixian, Director of the Innovation Center at Yaxin Group, delivered a speech titled “Development Trends in Cardiovascular Technology,” sharing several key areas where domestic companies can achieve breakthroughs and innovation in the current cardiovascular field.

He further stated, “The establishment of the Innovation Translation Center aims first to encourage more young physicians to propose innovative ideas, leverage the platform to facilitate the translation of their research achievements into practical applications, and ultimately achieve industrialization. Second, hospital-based research has historically been relatively fragmented; by building this platform, we can organize these disparate efforts. This will be highly beneficial for the hospital’s future development. We urgently need such a platform for translating innovative technologies, one that brings together hospitals, physicians, enterprises, and investment institutions to collaboratively advance innovation projects.”

Subsequently, Li Weiduo, Director of the Philips Solutions Advisory Team, shared insights on “Development Trends and Challenges in the Cardiovascular Industry,” introducing how Philips is focusing on data and information as its core to establish scenarios and layers for cardiovascular health management, thereby achieving comprehensive patient care throughout the entire journey. Zhou Ying, Vice President of Business Development and Marketing at Dimed Biologics, and Du Juan, Senior Manager of Statistical Analysis, presented on “Efficient Biometrics Strategies to Enhance Clinical Research Efficiency.” David Liu, CEO of Comede, shared on “Comede Empowering Clinicians to Engage in Medical Device Innovation.” Rita Feng from Maibo Medical discussed how to build a cardiovascular medical product industry chain encompassing “prevention, diagnosis, treatment, and rehabilitation.”

Li Weiduo, Director of the Philips Solutions Consulting Team, Shares “Development Trends and Challenges in the Cardiovascular Industry”

Hong Kong Asia Medical Center Co., Ltd. is dedicated to medical investments in Asia and hospital management, with hospitals and heart centers established in Hong Kong, Japan, and mainland China. Its subsidiary, Wuhan Asia Heart Hospital, was founded in 1999 and has become a national leader in the diagnosis of cardiovascular diseases. After years of development, it has grown into an influential Grade III specialized cardiovascular hospital both regionally and nationwide. The newly opened Wuhan Yaxin General Hospital in 2018 is a large-scale general hospital built according to the standards of a Grade III Class A facility. The hospital features 1,100 inpatient beds, 23 surgical operating rooms, and 13 interventional catheterization labs (including three DSA hybrid operating rooms). It serves as a comprehensive clinical medical center integrating medical care, teaching, scientific research, prevention, healthcare, emergency services (including air ambulance), and rehabilitation.

Legend Capital is an independent professional venture capital firm under Legend Holdings, established in April 2001. Its core business focuses on early-stage venture capital and growth-stage expansion investment, with a particular emphasis on TMT and innovative consumption, professional services and intelligent manufacturing, healthcare, and culture and sports sectors. The total assets under management in USD and RMB funds exceed RMB 45 billion, with a strong focus on innovation and growth opportunities in China. As of 2019, Legend Capital had invested in nearly 450 companies, among which approximately 70 have successfully listed or been quoted on domestic or overseas stock exchanges, and more than 50 have exited through mergers and acquisitions. Legend Capital has long been committed to supporting the growth of innovative healthcare enterprises in China, having cumulatively invested in nearly 90 companies in the healthcare sector. In 2014, Legend Capital made its initial investment in Hong Kong Asia Medical Center Limited.